11/18/2024 5:16 AM | Pontifax Management III G.P. Ltd. (0001726335) (Filed by) UroGen Pharma (Subject)
| Form SC 13D/A | |
11/14/2024 6:46 PM | Point72 Asset Management, L.P. (Filed by) UroGen Pharma (Subject)
| Form SC 13G/A | |
11/14/2024 4:46 PM | RA CAPITAL MANAGEMENT, L.P. (Filed by) UroGen Pharma (Subject)
| Form SC 13G/A | |
11/14/2024 11:04 AM | MENORA MIVTACHIM HOLDINGS LTD. (Filed by) UroGen Pharma (Subject)
| Form SC 13G/A | |
11/14/2024 7:37 AM | COWEN AND COMPANY, LLC (Filed by) UroGen Pharma (Subject)
| Form SC 13G/A | |
11/14/2024 5:44 AM | RTW INVESTMENTS, LP (Filed by) UroGen Pharma (Subject)
| Form SC 13G/A | |
11/12/2024 8:30 AM | Adage Capital Management, L.P. (Filed by) UroGen Pharma (Subject)
| Form SC 13G | |
|
11/08/2024 1:17 PM | BlackRock, Inc. (Filed by) UroGen Pharma (Subject)
| Form SC 13G | |
11/06/2024 12:50 PM | MORGAN STANLEY (Filed by) UroGen Pharma (Subject)
| Form SC 13G | |
11/06/2024 7:01 AM | UroGen Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/06/2024 7:04 AM | UroGen Pharma (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
10/24/2024 1:02 PM | BlackRock, Inc. (Filed by) UroGen Pharma (Subject)
| Form SC 13G | |
10/09/2024 3:21 PM | Degnan Chris (Reporting) UroGen Pharma (Issuer)
| Form 3 Initial statement of beneficial ownership of securities | |
10/09/2024 3:22 PM | Degnan Chris (Reporting) UroGen Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
10/09/2024 7:18 AM | UroGen Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
09/24/2024 3:15 PM | UroGen Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
09/12/2024 12:51 PM | Smith Jason Drew (Reporting) UroGen Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/12/2024 12:54 PM | Schoenberg Mark (Reporting) UroGen Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/12/2024 12:50 PM | Kim Dong (Reporting) UroGen Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/10/2024 6:16 AM | Schoenberg Mark (Reporting) UroGen Pharma (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
08/15/2024 7:00 AM | UroGen Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/13/2024 7:01 AM | UroGen Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/13/2024 7:05 AM | UroGen Pharma (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
08/08/2024 3:30 PM | UroGen Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/08/2024 8:06 AM | BUTITTA CYNTHIA M (Reporting) UroGen Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/08/2024 8:07 AM | UroGen Pharma (Issuer) WEN LEANA (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/08/2024 8:08 AM | Robinson James A. Jr. (Reporting) UroGen Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/08/2024 8:09 AM | Holden Stuart (Reporting) UroGen Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/08/2024 8:10 AM | UroGen Pharma (Issuer) Wildman Daniel George (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/08/2024 8:11 AM | Cohen Fred E (Reporting) UroGen Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/08/2024 8:11 AM | Belldegrun Arie (Reporting) UroGen Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/09/2024 4:30 PM | UroGen Pharma (Filer)
| Form ARS | |
06/24/2024 4:25 PM | COWEN AND COMPANY, LLC (Filed by) UroGen Pharma (Subject)
| Form SC 13G | |
06/24/2024 3:51 PM | Point72 Asset Management, L.P. (Filed by) UroGen Pharma (Subject)
| Form SC 13G | |
06/18/2024 4:07 PM | UroGen Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/13/2024 9:51 AM | UroGen Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/11/2024 12:15 PM | Schoenberg Mark (Reporting) UroGen Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/11/2024 5:16 AM | Schoenberg Mark (Reporting) UroGen Pharma (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
05/13/2024 7:01 AM | UroGen Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/13/2024 7:05 AM | UroGen Pharma (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
05/08/2024 1:22 PM | BlackRock Inc. (Filed by) UroGen Pharma (Subject)
| Form SC 13G/A | |
JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad) Trump's back in the White House, but Wall Street is pissed.
Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback. Get your free guide NOW before it's too late. |
04/29/2024 7:18 AM | UroGen Pharma (Filer)
| Form 10-K/A | |
03/20/2024 3:38 PM | Schoenberg Mark (Reporting) UroGen Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/18/2024 12:48 PM | Schoenberg Mark (Reporting) UroGen Pharma (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
03/14/2024 7:16 AM | UroGen Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
03/14/2024 7:17 AM | UroGen Pharma (Filer)
| Form 10-K Annual report pursuant to Section 13 or 15(d) | |
03/04/2024 6:00 AM | UroGen Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
03/01/2024 6:00 AM | UroGen Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/22/2024 8:23 AM | Arkin Moshe (Filed by) UroGen Pharma (Subject)
| Form SC 13D/A | |
02/14/2024 6:07 AM | RTW INVESTMENTS, LP (Filed by) UroGen Pharma (Subject)
| Form SC 13G | |
02/12/2024 4:47 PM | Kim Dong (Reporting) UroGen Pharma (Issuer)
| Form 4/A | |
02/12/2024 4:43 PM | Kim Dong (Reporting) UroGen Pharma (Issuer)
| Form 4/A | |
02/07/2024 3:15 PM | UroGen Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/05/2024 8:15 PM | Schoenberg Mark (Reporting) UroGen Pharma (Issuer)
| Form 4/A | |
02/05/2024 8:16 PM | Smith Jason Drew (Reporting) UroGen Pharma (Issuer)
| Form 4/A | |
02/02/2024 6:04 PM | Barrett Elizabeth A. (Reporting) UroGen Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/02/2024 6:05 PM | Kim Dong (Reporting) UroGen Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/02/2024 6:07 PM | Schoenberg Mark (Reporting) UroGen Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/02/2024 6:12 PM | Smith Jason Drew (Reporting) UroGen Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/02/2024 1:18 PM | BlackRock Inc. (Filed by) UroGen Pharma (Subject)
| Form SC 13G | |
02/01/2024 9:13 AM | Schoenberg Mark (Reporting) UroGen Pharma (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
02/01/2024 8:53 AM | Smith Jason Drew (Reporting) UroGen Pharma (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/17/2024 3:16 PM | UroGen Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
01/02/2024 7:04 AM | UroGen Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
12/29/2023 3:30 PM | RA CAPITAL MANAGEMENT, L.P. (Filed by) UroGen Pharma (Subject)
| Form SC 13G | |